BIMI International Medical Inc. (BIMI)
NASDAQ: BIMI · IEX Real-Time Price · USD
1.350
-0.040 (-2.88%)
At close: Jul 19, 2024, 4:00 PM
1.360
+0.010 (0.74%)
Pre-market: Jul 22, 2024, 6:16 AM EDT

BIMI Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018 2017 - 2006
Revenue
5.8511.8321.3212.8400
Upgrade
Revenue Growth (YoY)
-11.32%-44.51%65.98%---
Upgrade
Cost of Revenue
3.489.8818.8910.400
Upgrade
Gross Profit
2.371.952.432.4400
Upgrade
Selling, General & Admin
5.6711.98.216.260.990.21
Upgrade
Other Operating Expenses
5.395.3926.13000
Upgrade
Operating Expenses
11.0517.2934.346.260.990.21
Upgrade
Operating Income
-8.68-15.34-31.91-3.81-0.99-0.21
Upgrade
Interest Expense / Income
-0.040.170.190.080.010
Upgrade
Other Expense / Income
6.146.882.85-2.333.4516.57
Upgrade
Pretax Income
-14.78-22.39-34.96-1.56-4.44-16.79
Upgrade
Income Tax
-0.020.010.030.4300
Upgrade
Net Income
-14.76-22.39-34.99-2-4.44-16.79
Upgrade
Shares Outstanding (Basic)
631000
Upgrade
Shares Outstanding (Diluted)
631000
Upgrade
Shares Change
76.67%396.87%151.24%30.65%9.25%5.71%
Upgrade
EPS (Basic)
-2.59-8.38-65.12-8.80-27.50-112.00
Upgrade
EPS (Diluted)
-2.59-8.38-65.12-8.80-27.50-112.00
Upgrade
Free Cash Flow
-2.16-10.26-4.68-3.78-2.06-0.34
Upgrade
Free Cash Flow Per Share
-0.34-3.85-8.73-17.69-12.64-2.30
Upgrade
Gross Margin
40.55%16.48%11.38%19.02%--
Upgrade
Operating Margin
-148.46%-129.65%-149.68%-29.68%--
Upgrade
Profit Margin
-252.36%-189.29%-164.10%-15.55%--
Upgrade
Free Cash Flow Margin
-36.97%-86.69%-21.95%-29.40%--
Upgrade
EBITDA
-14.65-21.99-34.52-1.42-4.43-16.79
Upgrade
EBITDA Margin
-250.57%-185.90%-161.92%-11.07%--
Upgrade
Depreciation & Amortization
0.170.220.240.0600
Upgrade
EBIT
-14.82-22.22-34.77-1.48-4.43-16.79
Upgrade
EBIT Margin
-253.47%-187.79%-163.07%-11.51%--
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).